Tier 4 — mechanistic

Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin

Qiu Y, Li M, Zhang Y, Liu Y, Zhao Y, Zhang J, Jia Q, Li J
Asian journal of psychiatry 2022 67:102896

Bibliography

PubMed
PMID 34773803
DOI
10.1016/j.ajp.2021.102896
Funding
Indexed support: Tianjin Municipal Science and Technology Bureau. See the publication for grant details.
Competing interests
A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.

Study snapshot

DesignCompanion weight and adipokine analysis of a randomized trial
ModelHuman participants; see population
Sample65 enrolled; 49 completers, matching an earlier trial report
InterventionBerberine 900 mg/day versus placebo; leptin/adiponectin analysis
Duration8 weeks
EndpointsMetabolic or symptom outcomes; Inflammatory markers; Tolerability

What the study showed, in plain terms

This report linked weight differences with leptin changes during adjunctive treatment. Adiponectin did not show the same explanatory signal.

Key findings

  • This report linked weight differences with leptin changes during adjunctive treatment. Adiponectin did not show the same explanatory signal.

What this study can and cannot tell us

Likely companion analysis of PMID 33812218; not independent replication. A leptin correlation does not prove mediation.

Source detail: indexed abstract and bibliographic record; unavailable methods or disclosures are identified rather than assumed.

Related papers in the corpus

Tier 2
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial
Li M et al. · Psychiatry research · 2021
Tier 2
Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia
Li M et al. · European archives of psychiatry and clinical neuroscience · 2022
Tier 2
Berberine improves negative symptoms and cognitive function in patients with chronic schizophrenia via anti-inflammatory effect: a randomized clinical trial
Pu Z et al. · Chinese medicine · 2023
Tier 2
Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial
Chan M et al. · Psychiatry and clinical neurosciences · 2022
Tier 2
Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson's Disease Patients
Li J et al. · Contrast media & molecular imaging · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology